Market Capitalization (Millions $) |
19 |
Shares
Outstanding (Millions) |
38 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
29 |
Cash Flow (TTM) (Millions $) |
-21 |
Capital Exp. (TTM) (Millions $) |
0 |
Catalyst Biosciences Inc
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on developing novel medications for rare and debilitating diseases. The company utilizes its proprietary protease engineering platform to create therapeutics that target specific proteases in the body, regulating their activity to treat various disorders.
Catalyst Biosciences primarily focuses on developing therapies for diseases related to the complement and coagulation systems. These areas include rare bleeding disorders, hemophilia, and hereditary angioedema. The company's lead product candidate, marzeptacog alfa, is being developed as a subcutaneous therapy for individuals with hemophilia A or B with inhibitors.
Besides marzeptacog alfa, Catalyst Biosciences has a pipeline of additional drug candidates in various stages of development. The company aims to improve upon existing treatments or develop new therapies where there are currently unmet medical needs. Catalyst Biosciences collaborates with industry partners and academic institutions to drive research and development efforts.
The company's objective is to create novel treatments that have the potential to transform the lives of patients suffering from rare, serious, or chronic diseases. Through its innovative protease engineering technology and strategic partnerships, Catalyst Biosciences strives to bring new therapeutic options to patients and improve their quality of life.
Company Address: 12770 High Bluff Drive San Diego 92130 CA
Company Phone Number: 266-8674 Stock Exchange / Ticker: NASDAQ CBIO
CBIO is expected to report next financial results on March 29, 2024. |
|
|